Irrespective of the anti-Israel BDS movements (boycott, divestment and sanctions), independent of UN condemnations, and in defiance of criticism and pressure by Western policy makers – which should not be ignored nor hyperbolized – burgeoning foreign investments in Israel, and the upgraded scope and diversity of Israel’s global trade balance, constitute a most authentic measure of Israel’s global integration/standing and global confidence in Israel’s long-term viability. Once again, complex reality triumphs over superficial conventional “wisdom.”
Some 280 global high tech giants (mostly from the US) have given kudos to Israel’s economy, in general, and Israel’s brain power, in particular, by establishing research and development (R&D) centers in the Startup Nation. Thus, Intel operates four R&D centers, Microsoft – 2, IBM – 3 R&D centers, etc..
A few scores of these high tech giants are major bio-med companies, such as Johnson & Johnson, Philips, General Electric, Abbott Laboratories, Merck Serono, Foson Pharmaceuticals and Samsung, reflecting global appreciation of Israel’s unique capabilities and contribution in the areas of medical devices, pharmaceuticals and digital and mobile healthcare. In 2014, Israel’s bio-med sector raised an all-time record of $2bn, while the acquisition of Israeli bio-med companies during 2013-14 peaked at $2.9bn. Novartis, the world’s largest pharmaceutical company, plans to expand its investments in Israel, following its 2014 investments in three Israeli companies. Johnson & Johnson, Abbott Laboratories, Medtronic and Volcano (the world’s largest intravascular imaging company) participate in the $70mn Israeli bio-med venture capital fund, Tri Ventures, and Israel’s Shavit Capital raised $75mn from US investors, mostly from the bio-med sector.